ãçºæã®è©³çŽ°ãªèª¬æã[Detailed description of the invention]
æ¬çºæã¯æ°èŠãªã«ã«ãã¹ããªã«èªå°äœã«é¢ã
ãã
æ¬çºæã®ååç©ã¯æ°èŠååç©ã§ãããäžè¬åŒ
ãåŒäžïŒ²ã¯äœçŽã¢ã«ãã«åºããã¯ã€ãªãŠååå
ã¯ã¹ã«ããã«åºããïœã¯ïŒãïŒã®æŽæ°ããïŒã»ïŒ
äœã®ç¹ç·ã¯é£œåè¥ããã¯äºéçµåã倫ã
瀺ããã
ã§è¡šããããã«ã«ãã¹ããªã«èªå°äœã§ããã該å
åç©ã¯è¡å°æ¿åéæå¶äœçšåã³æ¶çäœçšãæãã
è¡æ äºé²è¬åã³æ¶çå€ãšããŠæçšã§ããã
äžè¬åŒïŒïŒã§è¡šããããååç©ã«ãããŠã
ã§ç€ºãããäœçŽã¢ã«ãã«åºãšããŠã¯ççŽ æ°ïŒãïŒ
ã®çŽéãããã¯åæç¶ã®ã¢ã«ãã«åºãæããããš
ãã§ããå
·äœçã«ã¯ã¡ãã«åºããšãã«åºãïœâã
ããã«åºãã€ãœãããã«åºãïœâããã«åºãtert
âããã«åºãsecâããã«åºçãäŸç€ºã§ããã
æ¬çºæã®ä»£è¡šçãªååç©ã以äžã«æ²ããã
ïŒâïŒïŒâãšããã·ã«ã«ããã«ãããã«ããªïŒâ
ïŒã»ïŒâãžãããã«ã«ãã¹ããªã«ãïŒâïŒïŒâãš
ããã·ã«ã«ããã«ãããã«ããªïŒâã«ã«ãã¹ããª
ã«ãïŒâïŒïŒâãããã·ã«ã«ããã«ãšãã«ããªïŒâ
ïŒã»ïŒâãžãããã«ã«ãã¹ããªã«ãïŒâã€ãœãã
ããã·ã«ã«ããã«ã¡ãã«ããªâã«ã«ãã¹ããªã«ã
ïŒâïŒïŒâãšããã·ã«ã«ããã«ãããã«ã¹ã«ãã
ã«ïŒâïŒã»ïŒâãžãããã«ã«ãã¹ããªã«ãïŒâïŒïŒ
âãšããã·ã«ã«ããã«ãããã«ã¹ã«ããã«ïŒâã«
ã«ãã¹ããªã«ãïŒâïŒïŒâtertâãããã·ã«ã«ã
ãã«ãããã«ã¹ã«ããã«ïŒâïŒã»ïŒâãžãããã«
ã«ãã¹ããªã«ãïŒâããããã·ã«ã«ããã«ã¡ãã«
ã¹ã«ããã«âïŒã»ïŒâãžãããã«ã«ãã¹ããªã«ã
ïŒâïŒïŒâtertâãããã·ã«ã«ããã«ãããã«ã
ãªïŒâïŒã»ïŒâãžãããã«ã«ãã¹ããªã«ãïŒâïŒïŒ
âã€ãœããããã·ã«ã«ããã«ãããã«ããªïŒâã«
ã«ãã¹ããªã«ãïŒâïŒïŒâã€ãœããããã·ã«ã«ã
ãã«ãããã«ã¹ã«ããã«ïŒâã«ã«ãã¹ããªã«ãïŒ
âïŒïŒâãšããã·ã«ã«ããã«ããã«ããªïŒâïŒã»ïŒ
âãžãããã«ã«ãã¹ããªã«
æ¬çºæã®ååç©ã¯çš®ã
ã®æ¹æ³ã«ãã補é ããã
ãããã®å¥œãŸããïŒäŸãæããã°äžåŒã«ç€ºãåŠã
å
¬ç¥ã®äžè¬åŒïŒïŒã§è¡šããããã«ã«ãã¹ããªã«
èªå°äœãã¯ãã«ã¹ã«ãã³åããŠäžè¬åŒïŒïŒã§è¡š
ããããã¯ãã«ã¹ã«ããã«èªå°äœãåŸã次ãã§äž
è¬åŒïŒïŒã®ååç©ãéå
ããŠäžè¬åŒïŒïŒã§è¡š
ããããã¡ã«ã«ããã«ã«ãã¹ããªã«èªå°äœãåŸã
æŽã«ã¢ã«ã«ãªã®ååšäžã«äžè¬åŒïŒïŒã®ååç©ãš
äžè¬åŒïŒïŒã§è¡šããããååç©ãšãåå¿ããã
ããšã«ããäžè¬åŒïŒïŒã®ååç©äžïŒžãã€ãªãŠå
åã§ããååç©ïŒâïŒã補é ãããããŸãäž
è¬åŒïŒâïŒã®ååç©ãé
žåããããšã«ããäž
è¬åŒïŒïŒã®ååç©äžïŒžãã¹ã«ããã«åºã§ããå
åç©ïŒâïŒã補é ãããã
äžè¬åŒïŒïŒã®ååç©ã®ã¯ãã«ã¹ã«ãã³ååå¿
ã¯ç¡æº¶åªã§ãããã¯éåžžçšããããäžæŽ»æ§æº¶åªã
äŸãã°ç¡«é
žãé
¢é
žãå¡©åã¡ãã¬ã³ããžã¯ãããšã¿
ã³ãã¯ãããã«ã ãåå¡©åççŽ çã®æº¶åªäžã§è¡ãª
ããããã¯ãã«ã¹ã«ãã³é
žã®äœ¿çšéã¯äžè¬åŒ
ïŒïŒã®ååç©ã«å¯ŸããŠéåžžïŒåã¢ã«ã倧éå°
éã奜ãŸããã¯ïŒãïŒåã¢ã«ã§ããã該åå¿ã®å
å¿æž©åºŠã¯éåžžâ20ã100âã奜ãŸããã¯â10âã
宀枩ã§ãããåå¿æéã¯éåžž0.5ã24æéã§ã
ãã
äžè¬åŒïŒïŒã®ååç©ã®éå
åå¿ã«ã¯éåžžè¡ãª
ãããŠããéå
æ¹æ³ãé©çšã§ããäŸãã°äºéæ«ã
éçã®éå±ãšç¡«é
žãå¡©é
žãããé
žãé
¢é
žçã®é
žãš
ãçšããæ¹æ³ãæããããšãã§ãããäžèšéå±å
ã³é
žã¯äžè¬åŒïŒïŒã®ååç©ã«å¯ŸããŠéåžžããã
ã倧éå°éçšãããããåå¿æž©åºŠã¯éåžžïŒã200
âã奜ãŸããã¯ïŒã100âã§ãããåå¿æéã¯é
åžžïŒã24æéã§ããã
äžè¬åŒïŒïŒã®ååç©ãšäžè¬åŒïŒïŒã®ååç©
ãšã®åå¿ã¯ãéåžžã®è±ããã²ã³åæ°ŽçŽ åå¿ã®æ¡ä»¶
äžã«è¡ãªããããçšããããè±ããã²ã³åå€ãšã
ãŠã¯çš®ã
ã®å¡©åºæ§ååç©ããããããšãã°ãæ°Žé
ž
åãããªãŠã ãæ°Žé
žåã«ãªãŠã ãçé
žãããªãŠ
ã ãçé
žã«ãªãŠã ãçé
žæ°ŽçŽ ãããªãŠã ãçé
žæ°Ž
çŽ ã«ãªãŠã ãçé
žéãªã©ã®ç¡æ©å¡©åºããããªãŠ
ã ãã«ãªãŠã ãªã©ã®ã¢ã«ã«ãªéå±ããããªãŠã ã¡
ãã©ãŒãããããªãŠã ãšãã©ãŒããªã©ã®ã¢ã«ã³ã©
ãŒããããªãšãã«ã¢ãã³ãããªãžã³ãã»ïŒ®âãž
ã¡ãã«ã¢ããªã³ãªã©ã®ææ©å¡©åºãæãããããæ¯
ããåå¿ã¯ç¡æº¶åªã§ãããããã¯æº¶åªã®åšåäžã§
ãè¡ãªããã溶åªãšããŠã¯åå¿ã«æªåœ±é¿ãäžããª
ãäžæŽ»æ§ã®ãã®ããã¹ãŠçšããããããšãã°ãã¡
ã¿ããŒã«ããšã¿ããŒã«ããããããŒã«ããã¿ããŒ
ã«ããšãã¬ã³ã°ãªã³ãŒã«ãªã©ã®ã¢ã«ã³ãŒã«é¡ããž
ãšãã«ãšãŒãã«ãããã©ããããã©ã³ããžãªããµ
ã³ãã¢ãã°ã©ã€ã ããžã°ã©ã€ã ãªã©ã®ãšãŒãã«
é¡ãã¢ã»ãã³ãã¡ãã«ãšãã«ã±ãã³ãªã©ã®ã±ãã³
é¡ããã³ãŒã³ããã«ãšã³ããã·ã¬ã³ãªã©ã®è³éŠæ
çåæ°ŽçŽ é¡ãé
¢é
žã¡ãã«ãé
¢é
žãšãã«ãªã©ã®ãšã¹
ãã«é¡ãã»ïŒ®âãžã¡ãã«ãã«ã ã¢ããããžã¡ã
ã«ã¹ã«ãããµã€ãããããµã¡ãã«ãªã³é
žããªã¢ã
ããªã©ã®éãããã³æ§æ¥µæ§æº¶åªãªã©ãæããã
ãããŸããæ¬åå¿ã¯æ²åãããªãŠã ãæ²åã«ãªãŠ
ã ãªã©ã®éå±æ²åç©ã®ååšäžã«è¡ãªãã®ãæå©ã§
ãããçšããããè©Šè¬ã®å²åã¯ç¹ã«éå®ãããåº
ç¯å²ã®äžããé©å®ã«éžæãããããéåžžäžè¬åŒ
ïŒïŒã®ååç©ã«å¯ŸããŠäžè¬åŒïŒïŒã®ååç©ã
çã¢ã«ãïŒåã¢ã«ã奜ãŸããã¯çã¢ã«ãïŒåã¢ã«
éã«ãŠçšããã®ãæãŸããããŸãããã®åå¿æž©åºŠ
ããšãã«éå®ãããªãããéåžžã宀枩ã200âã
奜ãŸããã¯50ã150âã§è¡ãªããããåå¿æéã¯
éåžžïŒã30æéã奜ãŸããã¯ïŒã15æéã§ããã
以äžã®åŠãããŠäžè¬åŒïŒâïŒã®æ¬çºæååç©
ã補é ãããã
äžè¬åŒïŒâïŒã®ååç©ã®é
žååå¿ã¯æ
£çšã®
é
žåå€ãäŸãã°éé
žåæ°ŽçŽ æ°Žãéé
¢é
žãéå®æ¯éŠ
é
žãã¡ã¿ã¯ããéå®æ¯éŠé
žçã®ææ©éé
žãç¡æ°Žã¯
ãã é
žãšç©ºæ°çãçšããŠè¡ãªããããæ¯ããé
žå
å€ã®äœ¿çšéã¯äžè¬åŒïŒâïŒã®ååç©ã«å¯ŸããŠ
éåžžïŒåã倧éå°éã奜ãŸããã¯ïŒãïŒåã¢ã«ã§
ããã該é
žååå¿ã¯éåžžã®äžæŽ»æ§æº¶åªãäŸãã°é
¢
é
žãããããªã³é
žãã¯ãããã«ã ãå¡©åã¡ãã¬
ã³ããžã¡ãã«ãã«ã ã¢ããçã®æº¶åªäžã§è¡ãªãã
ããåå¿æž©åºŠã¯éåžžâ20ã100âã奜ãŸããã¯ïŒ
ã50âã§ãããåå¿æéã¯éåžžïŒã24æéã§ã
ãã以äžã®åŠãããŠäžè¬åŒïŒâïŒã®æ¬çºæå
åç©ã補é ãããã
æ¯ãããŠåŸãããæ¬çºæååç©ã¯åå¿çµäºåŸåžž
æ³ã«åŸã€ãŠåå¿æ··åç©ããåé¢ããããäŸãã°å
å¿æ··åç©ã®æº¶å€ãçå»ãããã¯çšéããããšã«ã
ãåŸããããåŸãããååç©ãå¿
èŠã«å¿ãåå¥å
çµæ¶æ³ãã«ã©ã ã¯ãããã°ã©ãã€ãŒãèå±€ã¯ãã
ãã°ã©ãã€ãŒçã®éåžžã®æ¹æ³ã«ããæŽã«ç²Ÿè£œãã
ããšãã§ããã
æŽã«äžè¬åŒïŒïŒã«ãããïŒâCH2ïŒâoãææã®
ã¢ã«ãã¬ã³åºã«çœ®ãå€ãã€ãååç©ãäŸãã°ïŒâ
ïŒïŒâãšããã·ã«ã«ããã«âïŒâã¡ãã«ãããã«
ããªïŒâïŒã»ïŒâãžãããã«ã«ãã¹ããªã«ãïŒâ
ïŒïŒâãšããã·ã«ã«ããã«âïŒâã¡ãã«ãããã«
ã¹ã«ããã«ïŒâã«ã«ãã¹ããªã«ãæ¬çºæååç©ãš
åæ§ã®è¬ç掻æ§ãæããã
以äžã«å®æœäŸãæ²ããŠæ¬çºæãæŽã«æããã«ã
ãã
å®æœäŸ ïŒ
ã¯ããã¹ã«ããªã³é
ž30mlã«åå¡©åççŽ 40mlãå
ããŠå€éšæ°·ä»€ãæ¹æäžãïŒã»ïŒâãžãããã«ã«ã
ã¹ããªã«8.9ïœãå°éã¥ã€æ·»å ãããæ·»å åŸå®€æž©
äžæ¹æãïŒæéè¡ããåå¿çµäºåŸãåå¿æ¶²ãæ°·â
æ°ŽçŽ200mlã«æ³šãæåºæ¶ãåãæ°ŽæŽãããåŸã
ããçµæ¶ã也ç¥åŸã¯ãããã«ã ããåçµæ¶ããŠã
ç¡è²æ¿ç¶æ¶ã®ïŒâã¯ããã¹ã«ããã«âïŒã»ïŒâãž
ãããã«ã«ãã¹ããªã«13ïœãåŸãã
èç¹209ã212âïŒå解ïŒ
æ°·70ïœã«æ¿ç¡«é
ž13mlãå ãã溶液ãå€éšæ°·å·æ¹
æäžãïŒâã¯ããã¹ã«ããã«âïŒã»ïŒâãžããã
ã«ã«ãã¹ããªã«7.4ïœãå°éã¥ã€æ·»å ããåŸã宀
æž©æ¹æäžäºéæ«13ïœãå°éã¥ã€æ·»å ãããæ·»å åŸ
50ã60âã«ãŠïŒæéæ¹æãããåå¿åŸäžæº¶ç©ã
åããæ°ŽæŽåŸ0.5NâNaOH氎溶液100mlã«æº¶è§£ã
ãäžæº¶ç©ãå»ãããæ¯æ¶²ãå¡©é
žã«ãŠé
žæ§ãšããŠ
æåºæ¶ãåãæ°ŽæŽãããåŸãããçµæ¶ãæ°Žãã
åçµæ¶ããŠç¡è²éç¶æ¶ã®ïŒâã¡ã«ã«ããâïŒã»ïŒ
âãžãããã«ã«ãã¹ããªã«ã»H2O3.5ïœãåŸãã
èç¹170.5ã172.5â
ã»ïŒ®âãžã¡ãã«ãã«ã ã¢ãã40mlã«ïŒâã¡ã«
ã«ããâïŒã»ïŒâãžãããã«ã«ãã¹ããªã«ã®Na
å¡©2.0ïœãå ããŠæ¹æäžã50ã60âã«ãŠïœâãã
ã¢é
ªé
žãšãã«ãšã¹ãã«2.34ïœãå«ãã»ïŒ®âãžã¡
ãã«ãã«ã ã¢ãã10ml溶液ã30åéãèŠããŠæ»Žäž
ããã滎äžåŸå枩床ã«ãŠïŒæéæ¹æããå·åŸé£œå
é£å¡©æ°Ž200mlã«æ³šãã¯ãããã«ã ã§æœåºããïŒ100
mlÃïŒåïŒãã¯ãããã«ã å±€ãååæ°ŽæŽãããã
ã«é£œåNaHCO3æ°Žãæ°Žã§æŽæµããNa2SO4ã§ä¹Ÿç¥
ãããNa2SO4ãå»ããã¯ãããã«ã ãçå»ã
ããæ¿çž®æ®ãã¯ãããã«ã âç³æ²¹ãšãŒãã«ããå
çµæ¶ããŠãç¡è²éç¶æ¶ã®ïŒâïŒïŒâãšããã·ã«ã«
ããã«ãããã«ããªïŒâïŒã»ïŒâãžãããã«ã«ã
ã¹ããªã«1.8ïœãåŸãã
èç¹78.5ã81â
é©åœãªåæãçšãäžèšãšåæ§ã«ããŠäžèšååç©
ãåŸãã
ÎïŒâïŒïŒâãšããã·ã«ã«ããã«ãããã«ããªïŒâ
ã«ã«ãã¹ããªã« èç¹99ã101â
ÎïŒâã¡ããã·ã«ã«ããã«ã¡ãã«ããªâïŒã»ïŒâ
ãžãããã«ã«ãã¹ããªã« èç¹120.5ã123â
ÎïŒâïŒïŒâã€ãœããããã·ã«ã«ããã«ãããã«
ããªïŒâïŒã»ïŒâãžãããã«ã«ãã¹ããªã«
èç¹68ã70â
å®æœäŸ ïŒ
é
¢é
ž30mlã«ïŒâïŒïŒâãšããã·ã«ã«ããã«ãã
ãã«ããªïŒâïŒã»ïŒâãžãããã«ã«ãã¹ããªã«1.5
ïœã溶解ããã宀枩æ¹æäž30ïŒ
éé
žåæ°ŽçŽ æ°ŽïŒml
ãå ããŠãïŒæ¥éæŸçœ®ãããåå¿åŸãåå¿æ¶²ã飜
åé£å¡©æ°ŽçŽ300mlã«æ³šããæåºéãåããæ°ŽæŽ
åŸä¹Ÿç¥ãããåŸãããçµæ¶ãã¯ãããã«ã âç³æ²¹
ãšãŒãã«ããåçµæ¶ããŠãç¡è²éç¶æ¶ã®ïŒâïŒïŒ
âãšããã·ã«ã«ããã«ãããã«ã¹ã«ããã«ïŒâ
ïŒã»ïŒâãžãããã«ã«ãã¹ããªã«1.0ïœãåŸãã
èç¹116ã117â
é©åœãªåæãçšãäžèšãšåæ§ã«ããŠäžèšååç©
ãåŸãã
ÎïŒâïŒïŒâãšããã·ã«ã«ããã«ãããã«ã¹ã«ã
ãã«ïŒâã«ã«ãã¹ããªã« èç¹141ã143â
ÎïŒâã¡ããã·ã«ã«ããã«ã¡ãã«ã¹ã«ããã«âã«
ã«ãã¹ããªã« èç¹181ã183â
å®æœäŸ ïŒ
ã»ïŒ®âãžã¡ãã«ãã«ã ã¢ãã40mlã«ïŒâã¡ã«
ã«ããâïŒã»ïŒâãžãããã«ã«ãã¹ããªã«ã®Na
å¡©2.0ïœãå ããŠæ¹æäžã50ã60âã«ãŠïŒâãã
ã¢åèé
žãšãã«ãšã¹ãã«2.5ïœãå«ãã»ïŒ®âãž
ã¡ãã«ãã«ã ã¢ãã10ml溶液ã30åéãèŠããŠæ»Ž
äžããã滎äžåŸå枩床ã«ãŠïŒæéæ¹æããå·åŸé£œ
åé£å¡©æ°Ž200mlã«æ³šãã¯ãããã«ã ã§æœåºãã
ïŒ100mlÃïŒåïŒãã¯ãããã«ã å±€ãååæ°ŽæŽãã
ããã«é£œåNaHCO3æ°Žãæ°Žã§æŽæµããNaSO4ã§ä¹Ÿ
ç¥ãããNaSO4ãå»ããã¯ãããã«ã ãçå»ã
ãŠãçœè²çµæ¶ã®ïŒâïŒïŒâãšããã·ã«ã«ããã«ã
ãã«ããªïŒâïŒã»ïŒâãžãããã«ã«ãã¹ããªã«1.7
ïœãåŸããèç¹68ã71â
å
çŽ åæå€ C16H21O3NS
  
èšç®å€ 62.52 6.88 4.56
å®æž¬å€ 62.24 6.63 4.77
ãè¬çè©Šéšã
ãã€ãã€ãŒç¬¬927ã929é ïŒ1962幎ïŒã«èšèŒã®æ¹
æ³ã«æºããŠè¡å°æ¿åéé»æ¢äœçšã調ã¹ããå³ã¡è¡
å°æ¿åéé»æ¢äœçšãAGâåã®åéèš
ïŒaggregometerïŒããã©ã€ã¹ãã³ã»ãããŠãã¢ã¯
ããŠã¢ãªã³ã°ã»ã³ã³ããâïŒBryston
Manufacturing Co.ïŒè£œãçšããŠæž¬å®ãããå
ã
ãæ¡åããè¡æ¶²è©Šæã¯ã¯ãšã³é
žãããªãŠã ãšå
šè¡
液ã®æ··åç©ã§ãã®æ··åæ¯çã¯ïŒïŒïŒïŒå®¹éæ¯ïŒã§
ããã該詊æã1000rpmã§10åéé å¿åé¢ããŠã
è¡å°æ¿æ¿åºŠã®é«ãè¡æŒ¿ãplatelet rich plasmaã
ïŒä»¥äžãPRPâïŒããšããïŒãåŸããåŸããã
PRPâïŒãåé¢ããæ®ãã®è¡æ¶²è©Šæã3000rpmã§
15åéããã«é å¿åé¢ããŠè¡å°æ¿æ¿åºŠã®äœãè¡æŒ¿
ãplatelet poor plasmaãïŒä»¥äžãPPPããšããïŒ
ãåŸãã
åèšPRPâïŒäžã«å«ãŸããŠããè¡å°æ¿ã®æ°ãã
ã¬ããã€ãŒã»ã¯ãã³ã«ã€ãæ³ïŒBrecherâ
Clonkite MethodïŒã§æž¬å®ããPRPâïŒãPPPã§
åžéããŠã¢ããã·ã³ã»ãžãã¹ããšãŒãïŒADPïŒâ
èªçºåéè©Šéšã«äŸãããã300000ïŒmmïŒã®è¡å°æ¿
ãå«ãè©ŠæïŒä»¥äžãPRPâïŒããšããïŒã調補
ãããŸãã³ã©ãŒã²ã³âèªçºåéè©Šéšã«äŸãããã
450000ïŒmmïŒã®è¡å°æ¿ãå«ãè©ŠæïŒä»¥äžãPRPâ
ïŒããšããïŒã調補ããã
(1) ADPâèªçºåéæå¶è©Šéš
è©Šéšãã¹ãååç©ãäºãå®ããæ¿åºŠã§å«æã
ã溶液0.01mlã«äžèšã§èª¿è£œããPRPâïŒã0.6
mlå ããæ··åç©ã枩床37âã®æ枩槜ã«ïŒåéå
¥
ããã次ã«è©²æ··åç©ã«ADP溶液ã0.07mlå ã
ãããã®æ··åç©ã®éé床ã枬å®ããéé床ã®å€
åãæ¹æåšã®å転é床1100rpmã«ãŠåéèšãçš
ããŠæž¬å®ããããã®è©Šéšã«ãããŠçšãããã
ADP溶液ã¯ããªãŒã¬ã³ã»ããããŒã«ç·©è¡æ¶²ã
çšããæ¿åºŠã7.5Ã10-5Mã«ãªãããã«èª¿è£œã
ããã®ã§ãããè¡å°æ¿ã®åéãæ倧ãšãªã€ãæ
ç¹ïŒå
ã®éé床ãæ倧ãšãªã€ãæç¹ïŒã®åéç
ãäžèšã®åŒããç®åºããã
åéçïŒïœïŒâïœïŒïŒïœïŒâïœïŒÃ100
ããã§
a1ïŒPRPâïŒã®éé床
b1ïŒPPPã®éé床
c1ïŒè©Šéšååç©åã³ADPãæ··åããPRPâïŒã®
éé床
äžåŒã§ç®åºãããåéçãB1ãšããããŸã
è©Šéšååç©ã䜿çšããªã以å€ã¯äžèšãšåæ§ã«ã
ãŠè¡å°æ¿ãåéãããŠåéçãæ±ãããã®åé
çãã³ã³ãããŒã«ã®åéçA1ãšããã
è©Šéšååç©ã®è¡å°æ¿åéé»æ¢äœçšã¯ãã³ã³ã
ããŒã«ã®åéçã«å¯ŸããŠé»æ¢çïŒïŒ
ïŒãšããŠæ±
ããã
é»æ¢çïŒïŒ
ïŒïŒïŒ¡ïŒâïŒïŒïŒ¡ïŒÃ100
(2) ã³ã©ãŒã²ã³âèªçºåéæå¶è©Šéš
è©Šéšãã¹ãååç©ãäºãå®ããæ¿åºŠã§å«æã
ã溶液0.01mlã«äžèšã§èª¿è£œããPRPâïŒã0.6
mlå ããæ··åç©ã枩床37âã®æ枩槜ã«ïŒåéå
¥
ããã次ã«è©²æ··åç©ã«ã³ã©ãŒã²ã³æº¶æ¶²ã0.07ml
å ããããã®æ··åç©ã®éé床ã枬å®ããéé床
ã®å€åãæ¹æåšã®å転é床1100rpmã«ãŠåéèš
ãçšããŠæž¬å®ããããã®è©Šéšã«ãããŠã³ã©ãŒã²
ã³ã¯ã100mgã®ã³ã©ãŒã²ã³ã«ãªãŒã¬ã³ã»ããã
ãŒã«ç·©è¡æ¶²ïŒPH7.35ïŒïŒmlãå ããŠããã€ã¶
ãããã®äžæŸæ¶²ã䜿çšãããè¡å°æ¿ã®åéãæ
倧ãšãªã€ãæç¹ïŒå
ã®éé床ãæ倧ãšãªã€ãæ
ç¹ïŒã®åéçãäžèšã®åŒããç®åºããã
åéçïŒïœïŒâïœïŒïŒïœïŒâïœïŒÃ100
ããã§
a2ïŒPRPâïŒã®éé床
b2ïŒPPPã®éé床
c2ïŒè©Šéšååç©åã³ã³ã©ãŒã²ã³ãæ··åããPRP
âïŒã®éé床
äžåŒã§ç®åºãããåéçãB2ãšããããŸã
è©Šéšååç©ã䜿çšããªã以å€ã¯äžèšãšåæ§ã«ã
ãŠè¡å°æ¿ãåéãããŠåéçãæ±ãããã®åé
çãã³ã³ãããŒã«ã®åéçA2ãšããã
è©Šéšååç©ã®è¡å°æ¿åéé»æ¢äœçšã¯ãã³ã³ã
ããŒã«ã®åéçã«å¯ŸããŠé»æ¢çïŒïŒ
ïŒãšããŠæ±
ããã
é»æ¢çïŒïŒ
ïŒïŒïŒ¡ïŒâïŒïŒïŒ¡ïŒÃ100
è©Šéšååç©
No.1 ïŒâïŒãšããã·ã«ã«ããã«ãããã«ããªïŒ
âïŒã»ïŒâãžãããã«ã«ãã¹ããªã«
No.2 ïŒâïŒïŒâãšããã·ã«ã«ããã«ããããã·
ã¹ã«ããã«ïŒã«ã«ãã¹ããªã«
No.3 ïŒâã«ã«ãã¡ããã·âïŒã»ïŒâãžããã
ã«ã«ãã¹ããªã«
No.4 ïŒâïŒïŒâã«ã«ããã·ã€ãœããããã·ïŒâ
ïŒã»ïŒâãžãããã«ã«ãã¹ããªã«
No.5 ïŒâïŒïŒâã«ã«ããã·ãšããã·ïŒâïŒã»ïŒ
âãžãããã«ã«ãã¹ããªã«
No.6 ïŒâïŒïŒâã«ã«ããã·ãšããã·ïŒâïŒã»ïŒ
âãžãããã«ã«ãã¹ããªã«
No.7 ïŒâïŒïŒâãšããã·ã«ã«ããã«ãããã«ã
ãªïŒã«ã«ãã¹ããªã«
No.8 ïŒâïŒã¡ããã·ã«ã«ããã«ã¡ãã«ããªïŒâ
ïŒã»ïŒâãžãããã«ã«ãã¹ããªã«
No.9 ïŒâïŒïŒâã€ãœããããã·ã«ã«ããã«ãã
ãã«ããªïŒâïŒã»ïŒâãžãããã«ã«ãã¹ããªã«
No.10 ïŒâïŒïŒâãšããã·ã«ã«ããã«ãããã«
ã¹ã«ããã«ïŒâïŒã»ïŒâãžãããã«ã«ãã¹ããª
ã«
No.11 ïŒâïŒã¡ããã·ã«ã«ããã«ã¡ãã«ã¹ã«ã
ãã«ïŒã«ã«ãã¹ããªã«
No.12 ïŒâïŒïŒâãšããã·ã«ã«ããã«ããã«ã
ãªïŒâïŒã»ïŒâãžãããã«ã«ãã¹ããªã«
äžèšè©Šéšååç©ã®ãã¡No.1åã³No.2åã³No.7
ã12ã¯æ¬çºæã®ååç©ã§ãããNo.3åã³No.4ã¯
ç¹éæ51â1481å·å
¬å ±ã«èšèŒã®ååç©ã§ããã
No.5åã³No.6ã¯ç¹éæ51â82279å·å
¬å ±ã«èšèŒã®
ååç©ã§ããã
çµæãäžèšç¬¬ïŒè¡šã«ç€ºãã第ïŒè¡šã«ãããæ°å€
ã¯é»æ¢çïŒïŒ
ïŒãè¡šããã
The present invention relates to novel carbostyril derivatives. The compound of the present invention is a new compound and has the general formula [In the formula, R is a lower alkyl group, X is a sulfur atom or a sulfonyl group, n is an integer of 1 to 4, 3.4
Dotted lines at positions indicate saturation or double bonds, respectively. ]
It is a carbostyril derivative represented by The compound has platelet aggregation inhibiting action and anti-inflammatory action,
It is useful as a thromboprophylactic and anti-inflammatory agent. In the compound represented by the general formula (), R
The lower alkyl group represented by has 1 to 4 carbon atoms.
straight-chain or branched alkyl groups, specifically methyl, ethyl, n-propyl, isopropyl, n-butyl, tert.
Examples include -butyl group, sec-butyl group, and the like. Representative compounds of the present invention are listed below. 6-(3-ethoxycarbonylpropylthio)-
3,4-dihydrocarbostyryl, 6-(3-ethoxycarbonylpropylthio)-carbostyryl, 6-(2-butoxycarbonylethylthio)-
3,4-dihydrocarbostyryl, 6-isopropoxycarbonylmethylthio-carbostyryl,
6-(3-ethoxycarbonylpropylsulfonyl)-3,4-dihydrocarbostyryl, 6-(3
-ethoxycarbonylpropylsulfonyl)-carbostyryl, 6-(3-tert-butoxycarbonylpropylsulfonyl)-3,4-dihydrocarbostyryl, 6-propoxycarbonylmethylsulfonyl-3,4-dihydrocarbostyryl,
6-(3-tert-butoxycarbonylpropylthio)-3,4-dihydrocarbostyryl, 6-(3
-isopropoxycarbonylpropylthio)-carbostyryl, 6-(3-isopropoxycarbonylpropylsulfonyl)-carbostyryl, 6
-(4-ethoxycarbonylbutylthio)-3ã»4
-Dihydrocarbostyryl The compound of the present invention can be produced by various methods, but one preferred example is as shown in the following formula, by chlorosulfonating a carbostyryl derivative represented by the general formula (). ) to obtain a chlorosulfonyl derivative represented by the formula (), and then reduce the compound of the general formula () to obtain a mercaptocarbostyryl derivative represented by the general formula (),
Further, by reacting the compound of general formula () with the compound represented by general formula () in the presence of an alkali, a compound (-A) in which X in the compound of general formula () is a sulfur atom is produced. Further, by oxidizing the compound of general formula (-A), a compound (-B) in which X in the compound of general formula () is a sulfonyl group is produced. The chlorosulfonation reaction of the compound of general formula () can be carried out without a solvent or with a commonly used inert solvent.
For example, it is carried out in a solvent such as sulfuric acid, acetic acid, methylene chloride, dichloroethane, chloroform, or carbon tetrachloride. The amount of chlorosulfonic acid used is usually 2 times to a large excess, preferably 2 to 5 times, by mole, relative to the compound of general formula (). The reaction temperature for this reaction is usually -20 to 100°C, preferably -10°C to
The temperature is room temperature, and the reaction time is usually 0.5 to 24 hours. Conventional reduction methods can be applied to the reduction reaction of the compound of general formula (), such as zinc powder,
Examples include a method using a metal such as iron and an acid such as sulfuric acid, hydrochloric acid, phosphoric acid, or acetic acid. The above metals and acids are usually used in large excess amounts relative to the compound of general formula (). Reaction temperature is usually 0~200â
â, preferably 0 to 100â, and the reaction time is usually 1 to 24 hours. The reaction between the compound of general formula () and the compound of general formula () is carried out under normal dehydrohalogenation reaction conditions. There are various basic compounds that can be used as dehalogenating agents, such as inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, and silver carbonate; Examples include alkali metals such as, alcoholates such as sodium methylate and sodium ethylate, and organic bases such as triethylamine, pyridine, and N.N-dimethylaniline. Such reactions can be carried out without a solvent or in the presence of a solvent, and all inert solvents that do not adversely affect the reaction can be used, such as methanol, ethanol, propanol, butanol, ethylene glycol, etc. Alcohols, ethers such as diethyl ether, tetrahydrofuran, dioxane, monoglyme and diglyme, ketones such as acetone and methyl ethyl ketone, aromatic hydrocarbons such as benzene, toluene and xylene, esters such as methyl acetate and ethyl acetate, N - Aprotic polar solvents such as N-dimethylformamide, dimethyl sulfoxide, and hexamethyl phosphoric acid triamide, etc. can be mentioned. Further, this reaction is advantageously carried out in the presence of a metal iodide such as sodium iodide or potassium iodide. The ratio of the reagents used is not particularly limited and is appropriately selected from a wide range, but usually the proportion of the compound of the general formula () to the compound of the general formula () is 5 times the mole, preferably 1 mole to 5 times the mole of the compound of the general formula (). It is desirable to use twice the molar amount. Furthermore, the reaction temperature is not particularly limited, but is usually room temperature to 200°C,
Preferably it is carried out at 50 to 150°C. The reaction time is usually 1 to 30 hours, preferably 1 to 15 hours.
The compound of the present invention of general formula (-A) is produced as described above. The oxidation reaction of the compound of general formula (-A) is carried out using a conventional oxidizing agent, such as a hydrogen peroxide solution, an organic peracid such as peracetic acid, perbenzoic acid, or metachloroperbenzoic acid, chromic anhydride, and air. It can be done. The amount of the oxidizing agent used is usually 2 times to a large excess amount, preferably 2 to 4 times the amount of the compound of general formula (-A). The oxidation reaction is carried out in a conventional inert solvent such as acetic acid, propionic acid, chloroform, methylene chloride, dimethylformamide and the like. The reaction temperature is usually -20 to 100â, preferably 0
~50°C, and the reaction time is usually 1 to 24 hours. The compound of the present invention of general formula (-B) is produced as described above. After completion of the reaction, the compound of the present invention thus obtained is isolated from the reaction mixture according to a conventional method. For example, it can be obtained by distilling off or diluting the solvent of the reaction mixture. The obtained compound can be further purified, if necessary, by conventional methods such as fractional recrystallization, column chromatography, and thin layer chromatography. Furthermore, compounds in which (-CH 2 ) -o in the general formula () is replaced with a branched alkylene group, such as 6-
(3-ethoxycarbonyl-2-methylpropylthio)-3,4-dihydrocarbostyryl, 6-
(3-Ethoxycarbonyl-2-methylpropylsulfonyl)-carbostyryl also has the same pharmacological activity as the compound of the present invention. The present invention will be further clarified with reference to Examples below. Example 1 40 ml of carbon tetrachloride is added to 30 ml of chlorosulfonic acid, and 8.9 g of 3,4-dihydrocarbostyryl is added little by little under stirring under external cooling. After the addition, stir at room temperature for 3 hours. After the reaction is complete, put the reaction solution on ice.
Pour into approximately 200ml of water to remove the precipitated crystals and wash with water. The obtained crystals were dried and then recrystallized from chloroform.
13 g of 6-chlorosulfonyl-3,4-dihydrocarbostyryl are obtained as colorless plate-like crystals. Melting point: 209-212â (decomposition) To a solution of 70 g of ice and 13 ml of concentrated sulfuric acid, 7.4 g of 6-chlorosulfonyl-3,4-dihydrocarbostyryl was added little by little to a solution of 13 ml of concentrated sulfuric acid added to 70 g of ice while stirring at room temperature. Add 13g of powder little by little. After addition
Stir at 50-60°C for 2 hours. After the reaction, remove the insoluble matter, wash with water, and dissolve in 100 ml of 0.5N NaOH aqueous solution to remove the insoluble matter. The mother liquor is acidified with hydrochloric acid, and the precipitated crystals are collected and washed with water. The obtained crystals were recrystallized from water to give colorless needle-like crystals of 6-mercapto-3 and 4.
- Obtain 3.5 g of dihydrocarbostyryl.H 2 O.
Melting point 170.5-172.5â Sodium 6-mercapto-3,4-dihydrocarbostyryl in 40 ml of N-N-dimethylformamide
After adding 2.0 g of salt, 10 ml of N.N-dimethylformamide solution containing 2.34 g of r-bromobutyric acid ethyl ester was added dropwise at 50 to 60° C. over 30 minutes while stirring. After dropping, stir at the same temperature for 2 hours, cool, pour into 200 ml of saturated saline, and extract with chloroform (100 ml).
ml x 3 times). The chloroform layer is thoroughly washed with water, further washed with saturated NaHCO 3 water, water, and dried over Na 2 SO 4 . Na 2 SO 4 is removed and chloroform is distilled off. The concentrated residue was recrystallized from chloroform-petroleum ether to obtain 1.8 g of 6-(3-ethoxycarbonylpropylthio)-3,4-dihydrocarbostyryl in the form of colorless needles. Melting point: 78.5-81°C The following compound is obtained in the same manner as above using appropriate raw materials. Î6-(3-ethoxycarbonylpropylthio)-
Carbostyril Melting point 99-101â Î6-methoxycarbonylmethylthio-3,4-
Dihydrocarbostyryl Melting point 120.5-123â Î6-(3-isopropoxycarbonylpropylthio)-3,4-dihydrocarbostyryl
Melting point 68-70â Example 2 1.5 6-(3-ethoxycarbonylpropylthio)-3,4-dihydrocarbostyryl in 30 ml of acetic acid
Dissolve g in 2 ml of 30% hydrogen peroxide solution while stirring at room temperature.
Add and leave for 2 days. After the reaction, pour the reaction solution into about 300 ml of saturated saline, take out the amount of precipitate, wash with water, and then dry. The obtained crystals were recrystallized from chloroform-petroleum ether to give colorless needle-shaped 6-(3
-ethoxycarbonylpropylsulfonyl)-
1.0 g of 3,4-dihydrocarbostyryl is obtained.
Melting point: 116-117°C The following compound is obtained in the same manner as above using appropriate raw materials. Î6-(3-ethoxycarbonylpropylsulfonyl)-carbostyryl Melting point 141-143°C Î6-Methoxycarbonylmethylsulfonyl-carbostyryl Melting point 181-183°C Example 3 6-mercapto-3,4 in 40 ml of N·N-dimethylformamide -Sodium of dihydrocarbostyryl
After adding 2.0 g of salt, 10 ml of N.N-dimethylformamide solution containing 2.5 g of 5-bromovaleric acid ethyl ester was added dropwise at 50 to 60° C. over 30 minutes while stirring. After dropping, stir at the same temperature for 2 hours, cool, pour into 200 ml of saturated saline, and extract with chloroform (100 ml x 3). Wash the chloroform layer thoroughly with water,
Further wash with saturated NaHCO 3 water, water and dry with NaSO 4 . NaSO 4 was removed, chloroform was distilled off, and white crystals of 6-(4-ethoxycarbonylbutylthio)-3,4-dihydrocarbostyryl 1.7
get g. Melting point 68-71â Elemental analysis value C 16 H 21 O 3 NS C H N Calculated value 62.52 6.88 4.56 Actual value 62.24 6.63 4.77 <Pharmacological test> Platelet test according to the method described in Nature, pp. 927-929 (1962) The aggregation inhibition effect was investigated. In other words, the platelet aggregation inhibition effect was measured using an AG-type aggregometer (Bryston Manufacturing Company).
Manufacturing Co.). The blood sample collected from the rabbit was a mixture of sodium citrate and whole blood at a mixing ratio of 1:9 (volume ratio). The sample was centrifuged at 1000 rpm for 10 minutes,
platelet rich plasma
(hereinafter referred to as "PRP-1"). obtained
Separate PRP-1 and collect remaining blood sample at 3000 rpm.
Further centrifugation for 15 minutes produces platelet poor plasma (hereinafter referred to as "PPP").
get. The number of platelets contained in the PRP-1 was determined by the Bretcher-Cronkhite method.
Adenosine diphosphate (ADP) was measured by diluting PRP-1 with PPP.
A sample containing 300,000/ mm3 platelets (hereinafter referred to as "PRP-2") was prepared for the induced aggregation test, and also for the collagen-induced aggregation test.
A sample containing 450,000/ mm3 platelets (hereinafter referred to as âPRP-
3) was prepared. (1) ADP-induced aggregation inhibition test Add 0.6 ml of PRP-2 prepared above to 0.01 ml of a solution containing the compound to be tested at a predetermined concentration.
ml was added, and the mixture was placed in a constant temperature bath at a temperature of 37°C for 1 minute. Then 0.07 ml of ADP solution was added to the mixture. The permeability of this mixture was measured, and the change in permeability was measured using an agglomerometer at a stirrer rotation speed of 1100 rpm. used in this test
The ADP solution was prepared using Oren-Veronal buffer to a concentration of 7.5Ã10 â5 M. The aggregation rate at the time when platelet aggregation reached the maximum (the time when the light transmittance reached the maximum) was calculated using the following formula. Aggregation rate = c 1 - a 1 / b 1 - a 1 Ã 100 where a 1 : Permeability of PRP-2 b 1 : Permeability of PPP c 1 : Permeability of PRP-2 mixed with test compound and ADP Let the aggregation rate calculated by the above formula be B1 . In addition, platelets are aggregated in the same manner as above except that no test compound is used, and the aggregation rate is determined, and this aggregation rate is defined as the control aggregation rate A1 . The platelet aggregation inhibiting effect of the test compound was determined as the inhibition rate (%) relative to the aggregation rate of the control. Inhibition rate (%) = A 1 - B 1 / A 1 Ã 100 (2) Collagen-induced aggregation inhibition test Add 0.6 ml of PRP-3 prepared above to 0.01 ml of a solution containing the compound to be tested at a predetermined concentration.
ml was added, and the mixture was placed in a constant temperature bath at a temperature of 37°C for 1 minute. Next, add 0.07ml of collagen solution to the mixture.
added. The permeability of this mixture was measured, and the change in permeability was measured using an agglomerometer at a stirrer rotation speed of 1100 rpm. In this test, collagen was ground by adding 5 ml of Oren-Veronal buffer (PH7.35) to 100 mg of collagen, and the resulting supernatant was used. The aggregation rate at the time when platelet aggregation reached the maximum (the time when the light transmittance reached the maximum) was calculated using the following formula. Aggregation rate = c 2 â a 2 / b 2 â a 2 Ã100 where a 2 : Permeability of PRP-3 b 2 : Permeability of PPP c 2 : PRP mixed with test compound and collagen
Transmittance of -3 Let the aggregation rate calculated by the above formula be B2 . In addition, platelets are aggregated in the same manner as above except that no test compound is used, and the aggregation rate is determined, and this aggregation rate is defined as the control aggregation rate A2 . The platelet aggregation inhibiting effect of the test compound was determined as the inhibition rate (%) relative to the aggregation rate of the control. Rejection rate (%) = A 2 - B 2 /A 2 Ã100 Test compound No. 1 6-(ethoxycarbonylpropylthio)
-3,4-dihydrocarbostyryl No.2 6-(3-ethoxycarbonylpropoxysulfonyl)carbostyryl No.3 6-carbomethoxy-3,4-dihydrocarbostyryl No.4 5-(1-carboxyisopropoxy) â
3,4-dihydrocarbostyryl No.5 5-(2-carboxyethoxy)-3,4
-Dihydrocarbostyryl No.6 6-(2-carboxyethoxy)-3ã»4
-dihydrocarbostyryl No.7 6-(3-ethoxycarbonylpropylthio)carbostyryl No.8 6-(methoxycarbonylmethylthio)-
3,4-dihydrocarbostyryl No.9 6-(3-isopropoxycarbonylpropylthio)-3,4-dihydrocarbostyryl No.10 6-(3-ethoxycarbonylpropylsulfonyl)-3,4-dihydrocarbostyryl No.11 6-(methoxycarbonylmethylsulfonyl)carbostyryl No.12 6-(4-ethoxycarbonylbutylthio)-3,4-dihydrocarbostyryl No.1, No.2, and No.7 among the above test compounds
-12 are compounds of the present invention, No. 3 and No. 4 are compounds described in JP-A-51-1481,
No. 5 and No. 6 are compounds described in JP-A-51-82279. The results are shown in Table 1 below. The numbers in Table 1 represent the inhibition rate (%).
ãè¡šããtableã
ãè¡šããtableã